C
Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ · Healthcare · 1.3B
Closing price
$10.52
+3.04% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
13.6×
Enterprise value / EBITDAEV/EBITDA
-54.5×
Free cash flow yieldFCF yield
-4.0%
Return on equityROE
-25.0%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
0.2×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.